Jeffry S. Mann, Ph.D., counsels clients on strategically managing their intellectual property assets. Informed by his experience in IP issues in business transactions, he designs monetizable IP portfolios, prepares and prosecutes patent applications, performs due diligence, and drafts and negotiates licensing agreements. Jeffry defends his clients’ strategic IP assets against attacks by competitors and represents clients internationally in post-grant proceedings before the US Patent & Trademark Office (USPTO) and in oppositions before the European Patent Office (EPO). He is co-leader of the firm’s global life sciences interdisciplinary group and the leader of the San Francisco IP practice.
Jeffry’s practice encompasses pharmaceuticals, biosimilars, functionalized polymers, medical devices and implants, fuel cells, hydrogen and ion generators, laboratory equipment, diagnostics, bioremediation, separations, catalysis, biotechnology, materials, and coatings.
He has practical research experience in organic synthesis, including peptide and oligonucleotide synthesis, bioconjugate chemistry, and polymer synthesis and modification with a focus on polymers of use in water analysis and purification, waste water remediation, ion-exchange, and drug delivery.
Before practicing law, Jeffry served on the faculty of the Department of Radiology at the University of California, San Francisco. While there, he directed a chemical research program funded by private, federal, and industrial grants. In collaboration with scientists at the Contrast Media Laboratory and the Magnetic Resonance Science Center, he is developing biodegradable macromolecular drug delivery vehicles for contrast agents used in diagnostic imaging. As a postdoctoral fellow in the Department of Pharmacy, he developed functionalized nucleotides bearing novel fluorescent and intercalating agents.
He is named inventor on two US patents covering biodegradable drug delivery vehicles for polymeric contrast media. Jeffry has also authored or co-authored 27 peer-reviewed articles and two book chapters in the areas of organic synthesis, contrast media, and diagnostic medical imaging. He frequently speaks on current topics in US Patent Law, and US and international IP strategies in the United States, Europe, and Asia, and is the author of recent articles on the new biosimilars regime in the United States.
Recognized, Patent Law, San Francisco, The Best Lawyers in America (2023)
Ranked, Intellectual Property: Patent Prosecution, California, Chambers USA (2022)
Member, Practice Group of the Year, Intellectual Property, Law360 (2019)
Member, Litigation Department of the Year–Intellectual Property, The American Lawyer (2019)
Recommended, Industry focus: Healthcare: life sciences, The Legal 500 US (2017–2022)
Recognized, IAM Patent 1000: The World’s Leading Patent Professionals (2018–2022)
Life Sciences Star, Intellectual Property, LMG Life Sciences (2017–2022)
Life Sciences Star, Patent, LMG Life Sciences (2012–2015)
Recognized, "Top 25 Portfolio Managers/Patent Prosecutors," Daily Journal (2013)
Recognized, "Leading Intellectual Property Attorneys in California," Daily Journal (2009)
Recognized, "35 Leading Portfolio Managers, Patent Prosecutors, and Litigators," Daily Journal's Top IP Attorneys (2008)